Abstract
Ferric Carboxymaltose (FCM) is widely used in the treatment of anaemia of Chronic Kidney Disease (CKD). The clinicians must be alert of the rare adverse events such as hypersensitivity with subsequent doses of Ferric carboxymaltose. Here, we report a case of a 59-year-old male a known case of CKD, with anaemia and thrombocytopenia. Ferric carboxymaltose was the treatment of choice. There was a hypersensitivity reaction to the second dose whereas, the first dose was well tolerated. This case report indicates the onset of adverse reaction with ferric carboxymaltose with the second dose even though the first dose was well tolerated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
